aibioCDT Equity to do 1-for-10 reverse stock split effective July 17
Tickers CDT
The split takes effect July 17, 2026 and trades on a split-adjusted basis from July 20, reducing outstanding shares to approximately 631,077.
Key facts
- Company
- CDT Equity Inc. (NASDAQ: CDT)
- News type
- Listings
- Primary source
- CDT Equity Inc. 8-K (2026-07-16)
CDT Equity Inc. (Nasdaq: CDT) said on July 16, 2026 that its board of directors had approved a 1-for-10 reverse stock split of its common stock. The company said the split is intended to ensure continued compliance with the Nasdaq bid-price rule. The announcement was made in a press release furnished with a Form 8-K dated July 16, 2026.
The terms
The reverse stock split becomes effective at 5:00 p.m. Eastern Time on July 17, 2026. The company's common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market at market open on July 20, 2026, under the existing ticker symbol CDT. The release says Nasdaq approved that date for the split to take effect.
As of the effective time, every 10 shares of the company's issued and outstanding common stock will be combined into one share. The par value per share remains $0.0001. The company's stockholders had approved future reverse stock splits, their timing, and granted the board authority to determine future exact split ratios.
After the split, the common stock will trade under a new CUSIP number, 20678X601. The number of outstanding shares will be reduced to approximately 631,077. No fractional shares will be issued, and stockholders who would otherwise receive one will receive a proportional cash payment.
Proportional adjustments will be made to the number of shares issuable upon exercise of equity awards, convertible securities and warrants, and to the applicable exercise prices. The number of shares authorized and reserved under the company's equity incentive plans will also be adjusted.
Who handles the split
Continental Stock Transfer & Trust Co. will serve as the exchange agent. Registered stockholders holding shares electronically in book-entry form are not required to take any action. Shares held in brokerage accounts or in street name will be adjusted automatically, subject to each broker's particular processes. The release names no underwriter or placement agent for the split.
The company
CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., describes itself as a data-driven biopharmaceutical development company focused on identifying, enhancing and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company's annual report describes a strategy centered on unlocking the value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies.
The annual report describes a lean, asset-agnostic model. It says the company intends to seek an exit through third-party license deals after pre-clinical trials, and that it uses co-crystallization and solid-form technologies developed at its Cambridge facilities. It also says that, in partnership with Sarborg Limited, it applies AI-powered signature analysis to identify new uses for existing compounds.
Financial position
The XBRL data in the company's annual report show research and development expense of $5.1 million for the year ended December 31, 2025, up from $3.4 million for 2024. The net loss was $39.2 million for 2025, compared with $17.8 million for 2024. Cash from operations was negative $15.6 million for 2025, compared with negative $9.7 million for 2024.
Year-end cash and cash equivalents were $554,000 for 2024, and the XBRL data also show short-term investments of $600,000 at the end of 2024. The filings available at the date of the announcement give no year-end 2025 cash balance, so the cash on hand against the company's operating cash use is not known from them.
The risks ahead
The split does not change the company's finances. Cash from operations was negative $15.6 million for 2025 and the net loss was $39.2 million, against year-end 2024 cash and cash equivalents of $554,000. The annual report says the company will seek an exit through third-party license deals after pre-clinical trials, and the release says it will pursue licensing and strategic M&A, with no timetable. The release lists the effect of the split on the stock price and the ability to maintain the Nasdaq listing as forward-looking uncertainties, and CDT gives no assurance that it will achieve its expectations. The annual report also describes Sarborg as a related party.